Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (TSE:APS)
TSX:APS
Total Valuation
Aptose Biosciences has a market cap or net worth of $6.25M. The enterprise value is C$8.67M.
Market Cap$6.25M
Enterprise ValueC$8.67M
Share Statistics
Aptose Biosciences has 2,552,429 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,552,429
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aptose Biosciences’s return on equity (ROE) is 5.60 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)5.60
Return on Assets (ROA)-2.51
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.96M
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aptose Biosciences is -6.15. Aptose Biosciences’s PEG ratio is -1.11.
PE Ratio-6.15
PS Ratio0.00
PB Ratio-49.43
Price to Fair Value-34.40
Price to FCF-0.16
Price to Operating Cash Flow-13.53
PEG Ratio-1.11
Income Statement
In the last 12 months, Aptose Biosciences had revenue of 0.00 and earned -25.43M in profits. Earnings per share was -0.04.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-25.43M
Net Income-25.43M
EBITDA0.00
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -27.01M and capital expenditures 0.00, giving a free cash flow of -27.01M billion.
Operating Cash Flow-27.01M
Free Cash Flow-27.01M
Free Cash Flow per Share-10.58
Dividends & Yields
Aptose Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.37
52-Week Price Change-93.36%
50-Day Moving Average2.88
200-Day Moving Average9.02
Relative Strength Index (RSI)45.16
Average Volume (3m)4.03K
Important Dates
Aptose Biosciences upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Aptose Biosciences as a current ratio of 2.14, with Debt / Equity ratio of -121.51%
Current Ratio2.14
Quick Ratio2.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aptose Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aptose Biosciences EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -4.19.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-4.19
EV to Operating Cash Flow-4.19
Balance Sheet
Aptose Biosciences has $4.70M in cash and marketable securities with $8.98M in debt, giving a net cash position of $4.28M billion.
Cash & Marketable Securities$4.70M
Total Debt$8.98M
Net Cash$4.28M
Net Cash Per Share$1.68
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aptose Biosciences is $8.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.20
Price Target Upside234.67% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast79.63%